Resultados de la búsqueda 291-300 of 13283 for NAD+ Sublingual

1. Cirugía - Ensayos clínicos - Mayo Clinic

   Study Of Zanzalintinib In Combination With Immuno-Oncology Agents In Participants With Solid Tumors ... Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, ...

2. Hematología - Ensayos clínicos - Mayo Clinic

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

3. Hematología - Ensayos clínicos - Mayo Clinic

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

4. Hematología - Ensayos clínicos - Mayo Clinic

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

5. Cirugía - Ensayos clínicos - Mayo Clinic

   Rochester, Minn. The purpose of this study is to use a multimodal approach to mitral valve evaluation using cardiac CT and MRI, which have shown superior ...

6. Médicos y departamentos

   Ferri FF. Diabetic polyneuropathy. · Diabetic neuropathy. National Institute of Diabetes and Digestive and Kidney Diseases. · American Diabetes Association.

7. Hematología - Ensayos clínicos - Mayo Clinic

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

8. Hematología - Ensayos clínicos - Mayo Clinic

   The purpose of this study is to assess the presence of various molecular markers in histiocytic disorders. In addition to this, to review clinical records of ...

9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   SC nivolumab in-home treatment may be safe, tolerable and/or effective when compared to in-clinic treatment and may reduce the burden of cancer and improve the ...

10. Hematología - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...